MedTrace Logo

Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma

NCT05626985 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2024-04-01

No results posted yet for this study

Summary

Most hepatocellular carcinoma (HCC) cases were at advanced stage when diagnosis established. This study is intended to establish a clinical diagnostic model GAMAD for early-stage HCC and evaluate the diagnostic efficiency the same time. This study is a multicenter prospective study. Participants including healthy control,HCC, liver cirrhosis, hepatitis and benign tumor-like lesions are consecutively recruited into the cohort. All the blood samples are collected before any treatments and will be tested in single center in order to decrease bias.

Conditions

Interventions

DIAGNOSTIC_TEST

GAMAD

Blood samples are tested for tumor markers including PIVKA-II (DCP),AFP, ctDNA methylation and biochemical tests.

Sponsors & Collaborators

  • The First Hospital of Jilin University

    collaborator OTHER

  • Singlera Genomics Inc.

    lead INDUSTRY

Principal Investigators

  • Tian Yang, Ph.D · Eastern Hepatobiliary Surgery Hospital

  • Guoyue Lv, Ph.D · The First Hospital of Jilin University

  • Fengmei Wang · Tianjin Third Central Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-19
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05626985 on ClinicalTrials.gov